Man Group’s Fulcrum Therapeutics FULC Stock Holding History

Man Group’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$354K	Buy	46,119 +30,866	+202%	+$286K	﹤0.01%	2173
2025 Q4	$173K	Buy	+15,253	New	+$155K	﹤0.01%	2148
2024 Q4	–	Sell	-48,324	Closed	-$173K	–	2054
2024 Q3	$173K	Buy	+48,324	New	+$359K	﹤0.01%	1875
2024 Q2	–	Sell	-102,226	Closed	-$965K	–	2097
2024 Q1	$965K	Buy	102,226 +7,609	+8%	+$67.9K	﹤0.01%	1551
2023 Q4	$639K	Buy	+94,617	New	+$420K	﹤0.01%	1600
2023 Q1	–	Sell	-96,152	Closed	-$700K	–	2137
2022 Q4	$700K	Buy	96,152 +10,394	+12%	+$67.8K	﹤0.01%	1420
2022 Q3	$694K	Buy	+85,758	New	+$614K	﹤0.01%	1407
2022 Q2	–	Hold	0	–	–	–	1493

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Man Group's FULC Position: Q1 2026 in Review

Man Group increased its Fulcrum Therapeutics (FULC) stake by 202% in Q1 2026, buying an estimated $286K and bringing the position to 46,119 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #2173.

Man Group first reported a position in FULC in Q3 2022 and has held it in 7 quarters since. The position peaked at $965K in Q1 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Man Group held 46,119 shares of Fulcrum Therapeutics worth $354K as of Q1 2026.
Man Group bought 30,866 Fulcrum Therapeutics shares in Q1 2026, an estimated $286K.
Fulcrum Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #2173 holding.
Man Group first reported a position in Fulcrum Therapeutics in Q3 2022 and has held it in 7 quarters since.
Man Group's Fulcrum Therapeutics position peaked at $965K in Q1 2024.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.